Samsung Biologics, commissioned to produce Moderna vaccine

After producing undiluted liquid overseas, it is charged, labeled, and packaged in South Korea

A total of four vaccine-related contracts and MOUs during President Moon's visit to the U.S

Samsung BioLogics signed a contract with Moderna on the 22nd (local time) to commission the production of COVID-19 vaccines.

 

After producing undiluted corona vaccine abroad, Samsung BioLogics will charge and pack it in Korea.

 

Samsung BioLogics CEO John Lim and CEO Stéphane Bancel Moderna attended the "Korea-U.S.

 

Vaccine Company Cooperation Event" held in Washington, D.C.

 

on the same day and signed the same day.

 

Samsung BioLogics plans to start aseptic charging, labeling, and packaging of hundreds of millions of vaccines to markets outside the U.S.

 

starting in the third quarter.

 

"The Moderna vaccine is the most important vaccine for people around the world fighting COVID-19," said John Lim, CEO of Samsung BioLogics.

 

"We have set a quick production schedule for commercial procurement early in the second half of this year in response to global demand for vaccines." "We expect this contract to help us continue to expand our production capacity outside of the United States," said Juan Andres, chief technology officer (CTO).

 

This is the fourth contract by a foreign pharmaceutical company to be commissioned to produce in Korea by COVID-19 vaccine.

 

Earlier, AstraZeneca, Novavax, and Sputnik V vaccine of Russia signed a consignment production contract with a domestic company.

 

Among them, AstraZeneca vaccine is currently being supplied to South Korea.

 

At the event, there were three MOUs (Memorandum of Understanding) in addition to a modern contract with Samsung BioLogics.

 

The South Korean Ministry of Trade, Industry and Energy will cooperate with Moderna's investment support and business activities in Korea, while Moderna will make efforts to invest in and recruit mRNA vaccine production facilities.

 

Moderna also signed an MOU with the Korea National Institute of Health to develop an mRNA vaccine.

 

In addition, Novavax, SK Bioscience, and the MOHW signed MOU on research and development including COVID-19 vaccine.

 

A total of four contracts and MOUs, including those of Samsung BioLogics, are interpreted as the outcome of the South Korea-U.S.

 

summit on the previous day.

 

President Moon Jae-in and President Joe Biden is epidemic to empower a coordinated response by 21, a joint statement has promised to 'Global Alliance for Vaccines and build a global partnership'.